Category: business – Page 181
(Reuters) — Nearly a third of more than 40 large companies seeking U.S. bankruptcy protection during the coronavirus pandemic awarded bonuses to executives within a month of filing their cases, according to a Reuters analysis of securities filings and court records.
Under a 2005 bankruptcy law, companies are banned, with few exceptions, from paying executives retention bonuses while in bankruptcy. But the firms seized on a loophole by granting payouts before filing.
Six of the 14 companies that approved bonuses within a month of their filings cited business challenges executives faced during the pandemic in justifying the compensation.
Do you agree with these predictions?
The first few months of 2020 have radically reshaped the way we work and how the world gets things done. While the wide use of robotaxis or self-driving freight trucks isn’t yet in place, the Covid-19 pandemic has hurried the introduction of artificial intelligence across all industries. Whether through outbreak tracing or contactless customer pay interactions, the impact has been immediate, but it also provides a window into what’s to come. The second annual Forbes’ AI 50, which highlights the most promising U.S.-based artificial intelligence companies, features a group of founders who are already pondering what their space will look like in the future, though all agree that Covid-19 has permanently accelerated or altered the spread of AI.
“We have seen two years of digital transformation in the course of the last two months,” Abnormal Security CEO Evan Reiser told Forbes in May. As more parts of a company are forced to move online, Reiser expects to see AI being put to use to help businesses analyze the newly available data or to increase efficiency.
With artificial intelligence becoming ubiquitous in our daily lives, DeepMap CEO James Wu believes people will abandon the common misconception that AI is a threat to humanity. “We will see a shift in public sentiment from ‘AI is dangerous’ to ‘AI makes the world safer,’” he says. “AI will become associated with safety while human contact will become associated with danger.”
A ZDNet report, citing Samsung’s white paper, stated that the sector of the International Telecommunication Union (ITU) responsible for radio communication, ITU-R, is likely to commence their work to define a 6G vision in 2021.
The 3G took 15 years to be defined, while the time taken for the 5G was eight years.
Samsung last year also asserted that it would continue to invest and pre-study future business, including the sixth generation mobile network, reported GizChina.
The global health crisis is accelerating meta-trends and hurling civilization towards the transhuman future. The disruptors are being disrupted, and the rush is on to digitize and virtualize everything in weeks’ time that otherwise would have taken a few years to play out. Recent surveys show that we have compressed five years in business and consumer digital adoption within a couple of months. https://www.ecstadelic.net/top-stories/the-great-reset-2020-…-look-like
#GreatReset2020
Expert Opinion: We’ll remember this time of tremendous change when we all looked like masked robbers and hijackers, the time of accelerated digital transformation and virtualization, geopolitical polarity, transpired meta-trends such as having more leisur.
No industry will be spared.
The pharmaceutical business is perhaps the only industry on the planet, where to get the product from idea to market the company needs to spend about a decade, several billion dollars, and there is about 90% chance of failure. It is very different from the IT business, where only the paranoid survive but a business where executives need to plan decades ahead and execute. So when the revolution in artificial intelligence fueled by credible advances in deep learning hit in 2013–2014, the pharmaceutical industry executives got interested but did not immediately jump on the bandwagon. Many pharmaceutical companies started investing heavily in internal data science R&D but without a coordinated strategy it looked more like re-branding exercise with the many heads of data science, digital, and AI in one organization and often in one department. And while some of the pharmaceutical companies invested in AI startups no sizable acquisitions were made to date. Most discussions with AI startups started with “show me a clinical asset in Phase III where you identified a target and generated a molecule using AI?” or “how are you different from a myriad of other AI startups?” often coming from the newly-minted heads of data science strategy who, in theory, need to know the market.
However, some of the pharmaceutical companies managed to demonstrate very impressive results in the individual segments of drug discovery and development. For example, around 2018 AstraZeneca started publishing in generative chemistry and by 2019 published several impressive papers that were noticed by the community. Several other pharmaceutical companies demonstrated impressive internal modules and Eli Lilly built an impressive AI-powered robotics lab in cooperation with a startup.
However, it was not possible to get a comprehensive overview and comparison of the major pharmaceutical companies that claimed to be doing AI research and utilizing big data in preclinical and clinical development until now. On June 15th, one article titled “The upside of being a digital pharma player” got accepted and quietly went online in a reputable peer-reviewed industry journal Drug Discovery Today. I got notified about the article by Google Scholar because it referenced several of our papers. I was about to discard the article as just another industry perspective but then I looked at the author list and saw a group of heavy-hitting academics, industry executives, and consultants: Alexander Schuhmacher from Reutlingen University, Alexander Gatto from Sony, Markus Hinder from Novartis, Michael Kuss from PricewaterhouseCoopers, and Oliver Gassmann from University of St. Gallen.
Regeneron rose as much as 2.4% in the stock market today, touching a record high of 655.93. Shares seesawed in a small range Thursday before ending the day up a small fraction, at 640.63. The peak price topped Regeneron stock’s previous high of 653.53, touched on Tuesday. Regeneron is part of the IBD Biomed/Biotech group, which ranks No. 14 out of 197 industry groups tracked. The group is just off its all-time high, which it hit on June 23.
Regeneron Pharmaceuticals (REGN) jumped to an all-time high Thursday, its second of the week, as analysts remain bullish on Regeneron stock due to its coronavirus treatment and other businesses.
Panasonic has begun testing robotic mobility devices at the newly constructed Takanawa Gateway train station in Tokyo.
The effort is art of a plan to bring a series of automated services to the airport and surrounding facilities that are part of a massive redevelopment project in the surrounding Shinagawa business district.
Three mobility devices, essentially intelligent electric wheelchairs, will be used as a single group in the trial. The experiment will focus on ensuring the safety of passengers with mobility issues as they are transported throughout the huge facilities.
Google today announced that it has signed up Verizon as the newest customer of its Google Cloud Contact Center AI service, which aims to bring natural language recognition to the often inscrutable phone menus that many companies still use today (disclaimer: TechCrunch is part of the Verizon Media Group). For Google, that’s a major win, but it’s also a chance for the Google Cloud team to highlight some of the work it has done in this area. It’s also worth noting that the Contact Center AI product is a good example of Google Cloud’s strategy of packaging up many of its disparate technologies into products that solve specific problems.
“A big part of our approach is that machine learning has enormous power but it’s hard for people,” Google Cloud CEO Thomas Kurian told me in an interview ahead of today’s announcement. “Instead of telling people, ‘well, here’s our natural language processing tools, here is speech recognition, here is text-to-speech and speech-to-text — and why don’t you just write a big neural network of your own to process all that?’ Very few companies can do that well. We thought that we can take the collection of these things and bring that as a solution to people to solve a business problem. And it’s much easier for them when we do that and […] that it’s a big part of our strategy to take our expertise in machine intelligence and artificial intelligence and build domain-specific solutions for a number of customers.”
The company first announced Contact Center AI at its Cloud Next conference two years ago and it became generally available last November. The promise here is that it will allow businesses to build smarter contact center solutions that rely on speech recognition to provide customers with personalized support while it also allows human agents to focus on more complex issues. A lot of this is driven by Google Cloud’s Dialogflow tool for building conversational experiences across multiple channels.